COMPARISON OF CLASS-SPARING TO 3-DRUG REGIMENS FOR INITIAL HIV THERAPY

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这是一项III期随机、3臂开放标签研究，比较了以下三种方案用于HIV感染初始治疗的有效性：基于非核苷逆转录酶抑制物(NNRTI)的方案(efavirenz(EFV)司他夫定缓释(D4T XR)[或齐多夫定(ZDV)或替诺福韦(TDF)]EPVIR(3TC)、基于(Ritonavir)RTV增强型蛋白酶抑制物(PI)的lopinavir LPV/RTV d4T XR[或ZDV或TDF]3TC方案)，以及核苷逆转录酶抑制物(NI)激活方案(EFLPV/RTV)。这项研究将招募660名感染HIV-1、抗逆转录病毒(ARV)幼稚的男性和女性受试者，年龄为18岁。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase III, randomized, 3-arm, open-label study comparing the effectiveness of the following three regimens for the initial treatment of HIV infection: a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (efavirenz (EFV) + stavudine-extended release (d4T XR) [or zidovuidine (ZDV) or tenofovir (TDF)] + epivir (3TC), a (ritonavir) RTV-enhanced protease inhibitor (PI)-based regimen (lopinavir LPV/RTV + d4T XR [or ZDV or TDF] + 3TC), and, a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (EFV + LPV/RTV). This study will enroll 660 HIV-1-infected, ARV (antiretroviral)-naive male and female subjects >18 years of age.